BDSX
BIODESIX INC
Next earnings Aug 5, 2026 · consensus $-0.92 EPS, $26.5M rev
Last earnings +1.7% on 2026-05-04
$23.34
▲ +16.47%$23.34▲ +334.31%
over 1Y
L $5.01EODHDH $23.34
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+16.5%
1W+34.5%
1M+57.6%
3M+64.3%
YTD+261.3%
1Y+334.3%
Avoid
Conviction
Horizon
Medium (3–12mo)
Street · 11 analysts
Buy
Revenue grew 24.1% YoY; but unprofitable (net margin -39.8%).
Revenue (FY2025) $88.5M · FY2025
BIODESIX INC shows $88.5M in FY2025 revenue (+24.1% YoY), a -39.8% net margin.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $54.5M | $38.2M | $49.1M | $71.3M | $88.5M |
| Gross profit | — | — | — | — | — |
| Operating income | -$40.9M | -$50.6M | -$41.3M | -$34.5M | -$27.9M |
| Net income | -$43.2M | -$65.4M | -$52.1M | -$42.9M | -$35.3M |
| Diluted EPS | -$1.58 | -$1.55 | -$0.64 | -$6.64 | -$4.67 |
| Net margin | -79.2% | -171.3% | -106.2% | -60.2% | -39.8% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$261M
EV / EBITDA—
EV / Sales3.0
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-15.3%
FCF yield-10.2%
Quality & risk
ROIC (est.)—
Free cash flow-$23.5M
Total debt$50.0M
Net cash-$31.0M
Altman Z-Score-6.26 distress
Piotroski F-Score4/8
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY-93.2%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
Recent filings
all on EDGAR ↗SCHEDULE 13GFiling2026-06-18open ↗424B3Filing2026-06-01open ↗EFFECTFiling2026-05-29open ↗S-3Filing2026-05-21open ↗8-KPeriod ending 2026-05-192026-05-20open ↗SCHEDULE 13G/AFiling2026-05-15open ↗SCHEDULE 13G/AFiling2026-05-08open ↗10-QPeriod ending 2026-03-312026-05-04open ↗8-KPeriod ending 2026-05-042026-05-04open ↗SCHEDULE 13GFiling2026-04-28open ↗ARSPeriod ending 2025-12-312026-04-09open ↗DEFA14AFiling2026-04-09open ↗
Frequently asked
- Is BIODESIX INC (BDSX) a buy?
- BDSX currently carries a Avoid rating with 2/5 conviction, derived from its latest SEC filings. Revenue grew 24.1% YoY; but unprofitable (net margin -39.8%).
- What is BIODESIX INC's quality score?
- BDSX scores 46.23529411764705/100 (grade D) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001439725, latest 10-Q filed 2026-05-04) · EODHD · as of 6/26/2026, 7:15:17 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.